Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00110
2006-03-27
Prospective
None
Nil
Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
N/A
Jeffrey Wing Hong FUNG
Department of Medicine & Therapeutics, CUHK
852-2683-8525
jwhfung@cuhk.edu.hk
PWH
Jeffrey Wing Hong FUNG
Department of Medicine & Therapeutics, CUHK
852-2683-8525
jwhfung@cuhk.edu.hk
PWH
Effect of Theophylline to Prevent Contrast Induced Nephropathy in Patients With Renal Insufficiency
Effect of Theophylline to Prevent Contrast Induced Nephropathy in Patients With Renal Insufficiency
N/A
Hong Kong
Yes
2006-02-20
Coronary Heart Disease & Chronic Renal Insufficiency
Drug
Theophylline infusion in addition to N-acetylcysteine and saline hydration
once
No drug in addition to N-acetylcysteine and saline hydration
Inclusion: 1. Patient willing to sign informed consent form 2. Patient over 18 years of age 3. Patient undergoing coronary angiography or intervention 4. Patient with a serum creatinine 1.30 to 4.52 mg/dL (115 to 400 umol/l)
Exclusion: 1. Patient with known allergy to or have already taken N-acetylcysteine (Fluimucil), theophylline or contrast agents 2. Patinet is in acute renal failure (2 Cr level differ by 15% within 1 month) 3. Patient in cardiogenic shock 4. Patient with significant cardiac arrhythmia 5. Pregnant women 6. Patients with child bearing age without appropriate contraception 7. Current dialysis patient 8. Concomitant use of dopamine and mannitol
>18
N/A
Both Male and Female
Interventional
Randomized
Placebo
Open label
Parallel
2006-03-30
200
Unknown
Development of contrast nephropathy, defined as an increase in serum creatinine concentration of > and = 0.5 mg/dL, or a reduction in estimated glomerular filtration rate of > and = 25% of the baseline value, within 48 hours after the procedure
N/A
2011-04-01
ChiCTR-TRC-09000682
2010-05-04
|
|
|
|
---|---|---|---|
No documents yet. |